Biogen, Inc. is pushing ahead with the Phase IV confirmatory trial for Aduhelm (aducanumab-avwa) and released some new details about the study on 27 January, even as the chance of securing widespread reimbursement for the Alzheimer’s drug in the near-term appears unlikely.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?